Advances in organ-specific cancer research have significantly enhanced our understanding of cancer's unique biology and progression within different organs. Researchers are now focusing on how cancer cells behave differently in various tissues, which has led to more targeted therapies and personalized treatment plans. For instance, breakthroughs in breast cancer research have highlighted the role of specific genetic mutations in tumor development, allowing for therapies that target those mutations. Similarly, liver cancer research has uncovered the role of the liver's microenvironment in cancer growth, paving the way for treatments that disrupt these interactions. Advances in imaging technologies and biomarker identification have also allowed for earlier detection, improving prognosis and treatment outcomes. With ongoing progress in molecular profiling and organ-specific models, these advances are paving the way for more effective, tailored therapies, offering hope for improved survival rates across multiple cancer types.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation